Table 2A.
All patients | M0 patients | M1 patients | p = 0 | ||||
---|---|---|---|---|---|---|---|
Marker | Nr of patients | Nr positiv(%) | Nr of patients | Nr positiv(%) | Nr of patients | Nr positiv(%) | |
CD56 | 89 | 87 (98%) | 45 | 45 (100%) | 44 | 42 (96%) | 0.99 |
Chromogranin A | 57 | 36 (63%) | 27 | 19 (70%) | 30 | 17 (57%) | 0.28 |
Synaptophysin | 79 | 63 (80%) | 37 | 33 (89%) | 42 | 30 (71%) | 0.06 |
TTF1 | 71 | 64 (90%) | 41 | 37(90%) | 30 | 27 (90%) | 0.97 |
Hif-1-alpha | 44 | 44 (100) | 29 | 29 (100%) | 15 | 15 (100%) | n.a. |
CD 44 | 44 | 44 (100) | 29 | 29 (100%) | 15 | 15 (100%) | n.a. |
GLUT-1 | 36 | 43 (84%) | 28 | 25 (89%) | 15 | 11 (73%) | 0.19 |
PD-1, | 18 | 13 (72%) | 12 | 11 (92%) | 6 | 2 (33%) | 0.02 |
PD-L1 tumor | 19 | 2 (10%) | 13 | 2 (15%) | 6 | 0 (0%) | 0.80 |
PD-L1 stroma | 19 | 6 (32%) | 13 | 5 (38%) | 6 | 1 (17%) | 0.36 |
PD-L1 macrophages | 19 | 12 (63%) | 13 | 10 (76%) | 6 | 2 (33%) | 0.08 |
MIB-1 | 34 | n.a. | 12 | n.a. | 22 | n.a. | 0.86 |
n.a., not applicable.